Lausanne, Switzerland-based AC Immune SA thinks the best potential for treating Parkinson’s disease and other neurodegenerative diseases lies in prevention, using a combination of therapeutic vaccines and diagnostics that can distinguish one proteinopathy from another.
In a recent interview with In Vivo, CEO Andrea Pfeifer explained why recent advancement with alpha-synuclein PET tracer ACI-12589 offers...